Thursday, November 12, 2026
Trials tracker
ctDNA and molecular residual disease studies across tumor types. Phase and status are the values on the ClinicalTrials.gov record linked from each row. DYNAMIC-III is not listed here because it is registered with the Australian New Zealand Clinical Trials Registry, not an NCT id.
Phase 2 trial that uses serial ctDNA to detect residual disease after primary treatment for moderate- or high-risk early triple-negative breast cancer and to start pembrolizumab. ClinicalTrials.gov lists the status as unknown.
Institute of Cancer Research, United Kingdom
Phase 2/3 trial of whether ctDNA detection after resection of stage IIA colon cancer identifies patients who benefit from adjuvant chemotherapy. ClinicalTrials.gov lists the study as active, not recruiting.
NRG Oncology
Phase 2 study that starts atezolizumab when circulating tumor DNA becomes positive after radical cystectomy for muscle-invasive bladder cancer, before or alongside radiographic metastases.
Aarhus University Hospital
Phase 2 study that changes capecitabine, CAPOX, or FOLFIRI according to serial ctDNA after surgery for microsatellite-stable stage III or T4N0 stage II colon cancer. ClinicalTrials.gov lists the status as unknown.
IFOM ETS - The AIRC Institute of Molecular Oncology
Observational study of serial tumor-informed ctDNA after surgery for stage I to IV colorectal cancer, with clinician-directed therapy. ClinicalTrials.gov lists the status as unknown.
Natera, Inc.
Phase 3 randomized trial of trifluridine/tipiracil versus placebo in patients with resected colorectal cancer who test ctDNA-positive without radiographic recurrence. ClinicalTrials.gov lists the study as completed.
National Cancer Center Hospital East
Phase 3 trial of adjuvant durvalumab versus placebo in patients with resected stage II to III non-small cell lung cancer who become MRD-positive during surveillance without RECIST recurrence. ClinicalTrials.gov lists the study as completed.
AstraZeneca
Phase 3 randomized trial of adjuvant atezolizumab versus placebo in patients with muscle-invasive bladder cancer who are ctDNA-positive after cystectomy. ClinicalTrials.gov lists the study as active, not recruiting.
Hoffmann-La Roche
Phase 3 trial of niraparib versus placebo in patients with triple-negative or BRCA-mutated HER2-negative breast cancer who have ctDNA detected without radiographic recurrence. ClinicalTrials.gov lists the study as active, not recruiting, with 40 patients enrolled.
GlaxoSmithKline
Observational study of a ctDNA assay for recurrence detection after curative-intent treatment, with cohorts in bladder, lung, breast, melanoma, gastroesophageal, gastric, pancreatic, head and neck, ovarian, endometrial, kidney, and colorectal cancers. ClinicalTrials.gov lists the study as recruiting.
Guardant Health, Inc.
Observational study using serial ctDNA to infer recurrence risk in stage III and limited stage IV melanoma. ClinicalTrials.gov lists the study as completed.
Case Comprehensive Cancer Center
Phase 2/3 trial that assigns adjuvant chemotherapy according to whether circulating tumor DNA is detected after surgery for colon cancer. ClinicalTrials.gov lists the study as recruiting.
NRG Oncology
Prospective cohort using circulating tumor DNA and its methylation profile to monitor patients from before kidney cancer surgery through long-term follow-up, compared with imaging.
Jinling Hospital, China
Alliance A032103 randomizes patients after surgery for muscle-invasive urothelial cancer of the bladder, renal pelvis, ureter, or urethra according to ctDNA, escalating MRD-positive patients to nivolumab plus relatlimab versus nivolumab and comparing surveillance with nivolumab in MRD-negative patients.
National Cancer Institute
Phase 2 study in which patients with resected clear-cell renal cell carcinoma who would otherwise receive adjuvant pembrolizumab are observed if molecular residual disease is not detected, and continue pembrolizumab if it is.
University of Alabama at Birmingham
Randomized trial comparing ctDNA-guided adjuvant therapy with standard adjuvant therapy after radical resection of pancreatic cancer. ClinicalTrials.gov lists the study as recruiting, with a start date of June 1, 2025.
Ruijin Hospital
Pilot cohort study of a prostate-specific ctDNA panel to estimate how often minimal residual disease is detected six weeks after radical prostatectomy and how that result relates to early distant relapse.
Radboud University Medical Center
Diagnostic study collecting serial ctDNA in high-risk stage I, stage II, and stage III germ cell tumors to estimate positive predictive value for relapse, retroperitoneal histology, and progression after chemotherapy.
Indiana University
Observational study of whether ctDNA can be detected in T1 grade 3 urothelial bladder cancer and whether it changes across resection and instillation therapy.
University Hospital, Basel
Observational study of the Labcorp Plasma Detect assay in patients planned for curative-intent treatment of muscle-invasive urothelial carcinoma, with concordance between recurrence and ctDNA as the primary objective.
OHSU Knight Cancer Institute